Ranibizumab SPC Cut By Nearly Two Years In UK
Filing Error Slices Nearly Two Years Off Roche’s UK Lucentis Protection
A ruling by the High Court has cut almost two years from UK SPC protection for Roche's Lucentis ranibizumab brand, potentially offering biosimilar competitors the change to jump into the market early.
